Intrauterine devices

Bacterial Vaginosis No More Ebook

Homeopathic Remedy for Bacterial Vaginosis

Get Instant Access

In women who use a copper IUD as a contraceptive, the copper concentration in the fallopian tubes is elevated, but copper and cerulo-plasmin levels in the serum are not changed (Wollen 1994). A number of reports suggest thaL pregnancy in association with copper IUDs results in an increased rate of spontaneous abortions and preterm birth in the group in which the IUD remained in the uterus, compared with the group in which the IUD was removed or expelled. No increase in the rate of birth defects was documented. This is also to be expected with levonorgestrel-containing "intrauterine systems".

Recommendation. From the embtyotoxicity point of view, an IUD remaining in utero is no indication for termination of pregnancy or invasive diagnostic procedures. However, increased spontaneous abortion has been reported with retained lUDs.

References

ACOG Committee Opinion No. 342. induction of labor for vaginal birth after cesarean delivery. Obstet Gynaecol 2006; 108: 465-7.

Bellemin B. Carlier P. Vial T et al. Misoprostol exposure during pregnancy: a French collaborative study. Presentation at the 10th Annual Conference of the F.uropean Network of Teratology Information Services (ENTIS), Madrid, 1999.

Black RS, Lees C, Thompson C ct al. Maternal and fetal cardiovascular cffects of transdermal glyceryl trinitrate and intravenous rilodriiie. Obstet Gynecol 1999; 94: 572-6.

Bond GR, Van Zee A. Overdosage of misoprostol in pregnancy. Am | Obstet Gynecol 1994; 71: 561-2.

Castilla EE, Orioli !M. Teratogenicity of misoprostol: data from the Latin-American collaborative study of congenital malformations (ECLAMC). Am ) Med Genet 1994; 51: 161-2.

Crowther CA. I liller JE. Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002; CD 001060.

Da Silva dal Pizzol T. Pozzobon Knop F. Serrate Mengue S, Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reproduct Toxicol 2006: 22: 666-71.

David M, Halle H, Lichtenegger W et al. Nitroglycerin to facilitate fetal extraction during cesarean delivery. Obstet Gynecol 1998; 91: 119-24

Donders GG. Bacterial vaginosis during pregnancy: screen and treat? F.ur | Obstet Gynecol Reprod Biol 1999; 83: 1-4.

Donders GG. Treatment of sexually transmitted bacterial diseases in pregnant women. Drugs 2000; 59; 477-85.

F.inarson TR, Koren G, Mattice D et al. Maternal spermicide use and adverse reproductive outcome: a meta analysis. Am J Obstet Gynecol 1990: 162: 655-60.

El-Sayed Y, Holbrook RH |r, Gibson R et al. Diltiazem for maintenance tocolysis of preterm labor: comparison to nifedipine in a randomized trial. I Matern Fetal Med 1998; 7; 217-21.

Goldberg AB. Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl | Med 2001;344:38-47.

Goldenberg RL, The management of preterm labor Obstet Gynecol 2002; 100: 1020-37.

Gonzalez CH. Marques-Dias MJ. Kim CA et al, Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998:351: 1624-7.

Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol 2006: 108:986-9.

Grospietsch G, Fenske M. Kühn W. Pathophysiologic der Lungenödementstehung bei der tokolytischen Therapie mit Fenoterol. Arch Gynäkol 1981; 232: 504-12.

Higby K. Suiter CR. A risk-benefit assessment of therapies for premature labour. Drug Saf 1999; 21: 35-56.

l lofmeyr GJ, Milos D, Nikodem VC el al. Limb reduction anomaly after failed misoprostol abortion. S Afr Med J 1998: 88; 566-7.

lannet D, Abankwa A. Guyard B et al. Nicardipine versus salbutamol in the treatment of premature labor. A prospective randomized study. Eur ] Obstet Gynecol Reprod Biol 1997; 73: 11-16.

(ick H, Walker AM, Hothman KJ et al. Vaginal spermicides and congenital disorders. J Am Med Assoc 1981; 245; 1329-32.

Jocsoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28(Suppl 1); S57-65.

Katz VL. Fanner RM Controversies in tocolytic therapy. Clin Obstet Gynecol 1999; 42(4): 802-19.

Larsson PG. Fahraeus L. Carlsson B et al. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. Br J Obstet Gynaecol 2006; 113: 629-37.

Oei SG. Calcium channel blockers for tocolysis: a review of their role and safety fol lowing reports of serious adverse events. Eur J Obstet Gynecol 2006; 126: 137-45.

Orioli IM, Caslilla EE. Epidemiological assessment of misoprostol teratogenicity. Br I Obstet Gynaecol 2000: 107: 519-23.

Papatsonis DN, van Geijn H P, Ader H| et al. Nifedipine and ritrodine in the management of preterm labor: a randomized multicenter trial. Obstet Gynecol 1997; 90: 230-34.

Papatsonis DN. Kuk |H, van Geijn HP et al. Neonatal effects of nifedipine and rito-drine for preterm labor. Obstet Gynecol 2000; 95: 477-81.

Papatsonis DN, van Geijn HP. Beleker OP et al. I lemodynamic and metabolic effects after nifedipine and ritodrine tocolysis. Int | Gynaecol Obstet 2003; 82: 5-10,

Rosenstein !|. Stafford MK. Kitchen VS et al. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 1998; 177: 1386-90.

Schiff E. Sivan E, Terry S et al. Currently recommended oral regimens for ritodrine tocolysis result in extremely low plasma levels. Am J Obstet Gynecol 1993; 169: 1059-64.

Schüler L, Ashton PW, Sanseverino MT. Teratogenicity of misoprostol. Lancet 1992; 339: 437.

Schüler L. Pastuszak A, Sanseverino MTV et al, Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. Reprod Toxicol 1999; 13: 147-51.

Stafford MK, Ward H, Flanagan A et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 327-31.

Thayer IS, Hupp SC In utero exposure to terbulaline, Effects on infant behavior and maternal self esteem. | Obstet Gynecol Neonatal Nurs 1997; 27: 691-700.

van Geijn HP. Lenglet |E, Bolte AC. Nifedipine trials: effectiveness and safety aspects. Br J Obstet Gynaecol 2005: 112 (Suppl 1): 79-83.

Vermeulen GM. Bruinse HW Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double blind trial. Br I Obstet Gynaecol 1999; 106: 652-7.

Weidinger H, Wies! H, Die Behandlung des Spätabortcs und der drohenden Frühgeburl mil Thll65a in Kombination mit Isoptin. Z Geburtsh Perinalol 1973; 177: 233-7.

Wing DA, Caffaney CA. Vaginal misoprostol administration for cervical ripening and labor induction. Clin Obstet Gynecol 2006: 49: 627-41.

Wollen A L. Sandvei R. Skare A et al. The localization and concentration of copper in the fallopian tube in women with or without an intrauterine contraceptive device. Acta Obstet Gynecol Scand 1994; 73: 195-9.

Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group Br I Obstet Gynaecol 2001: 108: 133-42.

Yip S-K, Tse AO-K, Haines CJ et al. Misoprostol's effect on uterine arterial blood flow and fetal heart rale in early pregnancy. Obstet Gynecol 2000: 95: 232-5.

Was this article helpful?

0 0
Bacterial Vaginosis Facts

Bacterial Vaginosis Facts

This fact sheet is designed to provide you with information on Bacterial Vaginosis. Bacterial vaginosis is an abnormal vaginal condition that is characterized by vaginal discharge and results from an overgrowth of atypical bacteria in the vagina.

Get My Free Ebook


Post a comment